Genmab A/S - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GMAB Nasdaq 2836 www.genmab.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Genmab A/S

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons - May 29th, 2026 2:35 pm
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress - May 21st, 2026 3:00 pm
Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation Estimate - May 16th, 2026 6:19 pm
Morgan Stanley Maintains an “Equal Weight” Rating on Genmab A/S (GMAB) - May 13th, 2026 11:53 am
Capital Increase in Genmab as a Result of Employee Warrant Exercise - May 12th, 2026 11:46 am
Junk-Rated Firms Rush to Reprice Risky Debt as Demand Surges - May 12th, 2026 11:37 am
Major Shareholder Announcement - May 8th, 2026 1:05 pm
Is It Time To Reassess Genmab (CPSE:GMAB) After Mixed Multi‑Year Share Performance - May 8th, 2026 6:17 am
Genmab A/S Q1 Earnings Call Highlights - May 7th, 2026 2:58 pm
DARZALEX royalties drive Genmab’s Q1 revenue higher amid expansion push - May 7th, 2026 12:46 pm
Genmab Announces Financial Results for the First Quarter of 2026 - May 7th, 2026 9:02 am
Genmab (GMAB) Rated Outperform on Oncology Pipeline - May 2nd, 2026 11:51 am
Genmab A/S (GMAB) Rating Lifted by Goldman Sachs on Strong 2026 Catalyst Outlook - Apr 24th, 2026 7:42 am
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains? - Apr 22nd, 2026 8:10 am
Genmab gains as Goldman upgrades stock to Buy on increased pipeline confidence - Apr 22nd, 2026 4:14 am
Genmab (CPSE:GMAB) Valuation Check After Mixed Recent Share Performance - Apr 20th, 2026 3:05 am
Genmab A/S Share Capital Reduction - Apr 17th, 2026 8:56 am
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026 - Apr 14th, 2026 4:23 am
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer - Apr 13th, 2026 7:35 am
A Look At Genmab’s (CPSE:GMAB) Valuation After Recent Share Price Volatility - Apr 1st, 2026 6:18 am